interferon alfa-2b | Lifeferon solution for v / m, subconjunctiva injected and instilled into the eye 3 million IU 1 ml vials 5 pcs.

Latin name

Lifferon

Release form

Lyophilisate for preparation of solution for intramuscular, subconjunctival injection and instillation into the eye



packaging 5 pcs

Pharmacological action

Lifeferon has antiviral, antitumor and immunomodulatory activity. Long-term use of the drug in individuals can cause the appearance of antibodies to interferon, which leads to a decrease in effectiveness.

acute and severe early-onset: until the 5th day of jaundice at a later date, the drug is less effective, with developing hepatic coma and the cholestatic course of the disease, the drug is ineffective)

of acute prolonged hepatitis B and C, chronic active hepatitis B, C and D without signs of cirrhosis and with signs of liver cirrhosis

viral (influenza, adenovirus, enterovirus, herpetic, mumps), virus-bacterial and mycoplasma meningoencephalitis (the use of the drug is most effective in the first 4 days of the disease)

viral conjunctivitis, keratoconjunctivitis, keratitis, keratouveitis

kidney cancer stage IV, hairy cell leukemia, malignant cell carcinoma, reticulosis, -cellular and squamous cell skin cancer, keratoacanthoma, chronic myelogenous leukemia, histiocytosis-X, subleukemic myelosis, essential thrombocytopenia

multiple sclerosis.

For children as part of complex therapy:

of acute lymphoblastic leukemia in remission after inductive chemotherapy (for 4-5 months of remission)

juvenile respiratory laryngeal papillomatosis starting from the day after the removal of papillomas.

Contraindications

severe allergic disease

pregnancy.

Use during pregnancy and lactation

The drug is contraindicated in pregnancy.

Composition of

1 ampoule contains:

Active ingredient: interferon alfa-2b human recombinant 3 million IU

Excipients: sodium chloride, sodium hydrogen phosphate dodecahydrate, sodium dihydrogen phosphate dihydrate, D-sorbitol, urine.

Dosage and administration

i / m administration. The average daily dose of 1 million ME / day.

Perifocal administration of

In case of basal cell and squamous cell carcinoma, keratoacanthoma, the drug is administered under the lesion at a rate of 1 million ME 1 time per day for 10 days. In the case of severe local inflammatory reactions, administration under the lesion is carried out after 1-2 days. At the end of the course, if necessary, cryodestruction is performed.

Subconjunctival administration of

For stromal keratitis and keratoiridocyclitis, subconjunctival injections of Lifeferon are prescribed in a dose of 60 thousand ME (in volume 0. 5 ml) daily or every other day depending on the severity of the process. Injections are performed under local anesthesia with 0.5% dicaine solution. The course of treatment is from 15 to 25 injections.

Topical application of

In conjunctivitis and superficial keratitis, 2 drops of Leiferon solution 6-8 times a day are applied to the conjunctiva of the affected eye. As the inflammatory phenomena disappear, the number of instillations is reduced to 3-4 times a day. The course of treatment is 2 weeks.

Side effects of

On the part of the body as a whole: with parenteral administration, chills, fever, fatigue, headache, malaise, and flu-like syndrome are possible. These side effects are partially stopped by paracetamol.

From the side of the organ of vision: with topical application, conjunctival infection, hyperemia of the mucous membrane of the eye, single follicles, edema of the conjunctiva of the lower arch are possible.

On the part of laboratory parameters: leukopenia, lymphopenia, thrombocytopenia, increased activity of ALT, alkaline phosphatase. For the timely detection of these deviations during therapy, general clinical blood tests must be repeated every 2 weeks, and biochemical - every 4 weeks. As a rule, these changes are usually minor, asymptomatic and reversible.

In case of severe adverse reactions or if they persist for a long time, a temporary dose reduction is allowed (with a decrease in the number of platelets less than 50 000 / μl, the absolute number of neutrophils less than 750 / μl) or interruption of treatment (with a decrease in the number of platelets less than 25 000 / μl, the absolute number of neutrophils is less than 500 / μl).

Drug Interaction

When co-administered with interferon alfa-2b, it is able to reduce the activity of microsomal liver enzymes of the cytochrome P450 system and, therefore, to affect the metabolism of cimetidine, phenytoin, dipyridamole, theophylpatin, diaphthalin, diapirin

The drug may enhance the neurotoxic, myelotoxic or cardiotoxic effects of drugs previously or concurrently administered.

Storage Conditions

The product should be stored in a dark place and out of the reach of children at 2 ° to 8 РC.

Shelf life

2 years

Deystvuyushtee substance

interferon alyfa-2b

dosage form

injection